Glenmark Pharmaceuticals Inc., USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials, previously held by Aspen Pharma USA Inc., with the market generating approximately $15.2 million in annual sales as of January 2025.